Precision Care Unleashed
When & Where
About this Track:
"Precision Care Unleashed" delves into the major trends for where Healthcare is headed - technology trends, digital transformation and the long term outlook for the healthcare and healthtech market.
Daniel Kraft will give an inspiring opening keynote, discussing the Future of Healthcare in his compelling session "Future-Back: Where is Healthcare Going".
Prat Vemana, CDO of Kaiser Permanente will then provide insight about the 5 key elements that are essential to successfully drive rapid, effective, and measurable transformation in Healthcare.
The third session will feature Abinhav Shashank, CEO of Innovaccer, Chris Waugh, Chief Innovation Officer of Sutter Health, and Prat Vemana, CDO of Kaiser Permanente to discuss how integrating, normalizing and activating healthcare data can unleash a new wave of innovation and create better healthcare outcomes for all.
Next, hear from Lisa Davis, CIO of Blue Shield of California and Dwight French, Healthcare Lead at Red Hat, dive into how Blue Shield of California is leveraging Red Hat for their digital transformation strategy, delivering their vision for Health Reimagined, in a moderated session by Diane Brady of Forbes.
The following panel session, "Precision Medicine" will dive into AI-enabled Drug Discovery and its effect on the future of therapeutics as we know them. Precision Medicine is the future of cancer. It touches all aspects from Bench to Bedside. The panel will cover various perspectives on Precision Medicine: from Drug development, Diagnostics, Treatment, and AI-enabled Bioinformatics. Led by Zenia Tata, Innovation consultant and former Chief Growth Officer of XPrize speak with industry leaders about how Artificial Intelligence is changing the outlook for precision medicine.
The track will culminate in an inspiring investment based session moderated by Jon Norris of the Silicon Valley Bank, where we will examine the key trends of the healthcare technology marketplace- what are the "hot button" trends that are changing care in 2022?
Join us on May 6th to Imagine, and Experience Precision Care Unleashed!
Track Agenda
- 05/06/2022 | 9:00 am – 9:20 am PDT
- 20 mins Hall ASpeakers
Daniel KraftPhysician-Scientist and Innovator
XPRIZE, Singularity UniversityDaniel Kraft is a Stanford and Harvard-trained physician-scientist, inventor, entrepreneur, and innovator and is serving as the Chair of the XPRIZE Pandemic Alliance Task Force. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has served as faculty chair for Medicine at Singularity University since its inception in 2008, and is founder and chair of Exponential Medicine, a program that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare. Following undergraduate degrees from Brown University and medical school at Stanford, Daniel was Board Certified in both Internal Medicine & Pediatrics after completing a Harvard residency at the Massachusetts General Hospital & Boston Children's Hospital, and fellowships in hematology, oncology, and bone marrow transplantation at Stanford.
He is often called upon to speak to the future of health, medicine and technology and has given four TED and two TEDMED Talks and has delivered keynotes to a diverse array of organizations.
He has multiple scientific publications (including in Nature and Science) and medical device, immunology, and stem cell-related patents through NIH-funded faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at the University of California San Francisco.
Daniel is a member of the Kaufman Fellows Society (Class 13) and a member of the Inaugural (2015) class of the Aspen Institute Health Innovators Fellowship.
Daniel's academic research has focused on: stem cell biology and regenerative medicine, stem cell-derived immunotherapies for cancer, bioengineering human T-cell differentiation, and humanized animal models. His research has been published in journals that include Nature and Science. His clinical work has focused on: bone marrow / hematopoietic stem cell transplantation for malignant and non-malignant diseases in adults and children, medical devices to enable stem cell based regenerative medicine, including marrow derived stem cell harvesting, processing and delivery.
He is heavily involved in digital health, founded Digital.Health, and is on the board of Healthy.io and advises several Fortune-50 and digital health-related startups. Daniel recently founded IntelliMedicine, focused on personalized, data-driven, precision medicine. He is also the inventor of the MarrowMiner, an FDA-approved device for the minimally invasive harvest of bone marrow, and founded RegenMed Systems, a company developing technologies to enable adult stem cell-based regenerative therapies.
Daniel is an avid pilot and has served in the Massachusetts and California Air National Guard as an officer and flight surgeon with F-15 & F-16 fighter Squadrons. He has conducted research on aerospace medicine that was published with NASA, with whom he was a finalist for astronaut selection
-
- 05/06/2022 | 9:20 am – 9:35 am PDT
- 15 mins Hall ASpeakers
Prat Vemana joined Kaiser Permanente in August 2019 as the organization’s first-ever Chief Digital Officer. In this role, Prat leads cross-functional teams across Kaiser Permanente to transform a full range of online and mobile interactions and digital experiences for its more than 12 million members, patients, clinicians and customers, as well as digital tools and processes for its workforce. Prat brings a wealth of experience leading this type of work across large scale, highly-matrixed organizations and will be instrumental in driving this shift across Kaiser Permanente.
Prior to Kaiser Permanente, Prat served as Chief Product and Experience Officer at The Home Depot where he was responsible for a consumer-centric product vision and strategy and driving user experience excellence across the company. He also served as vice president of Interconnected Experience at Home Depot, successfully launching a new digital online experience and cloud based-technology platform. Prat’s prior roles include vice president of Global Ecommerce, Product Management, and Analytics at Staples, Inc. and vice president of Product Development at Informed Clinical Sciences Corporation.
Prat holds a bachelor’s degree in computer science and engineering from the University of Madras and a master’s in business administration in global leadership and innovation from MIT’s Sloan School of Management.
-
- 05/06/2022 | 9:35 am – 10:05 am PDT
- 30 mins Hall ASpeakers As Sutter Health’s first Chief Innovation Officer, Chris Waugh applies his extensive experience in human-centered design to guide the integrated network’s innovation strategy. Human-centered design is a creative approach that seeks personalized solutions to meet individual needs — understanding people and their behaviors, identifying trends and exploring solutions that improve a person’s healthcare experience — in order to make healthcare more usable and accessible for patients, doctors and nurses. At Sutter, Waugh has spearheaded the digital transformation of healthcare and the implementation of Tera — a virtual-first medical practice which aims to best resolve issues before patients have to schedule an in-person appointment. This work is driven by the idea that healthcare should fit into the patient’s life, and not the other way around. He is also passionate about taking on mental health issues and driving simpler, easier to navigate and more resonate healthcare for all patients.
Before joining Sutter Health, Waugh held entrepreneurial leadership roles at IDEO, a globally regarded Bay Area design and innovation firm, and was vice president of design at One Medical Group in San Francisco where he helped create a culture of innovation.
He is an affiliated member of both Rock Health and Innovation 50.
Waugh graduated from Fort Lewis College in Colorado, with bachelor’s degrees in international business and French. Prat Vemana joined Kaiser Permanente in August 2019 as the organization’s first-ever Chief Digital Officer. In this role, Prat leads cross-functional teams across Kaiser Permanente to transform a full range of online and mobile interactions and digital experiences for its more than 12 million members, patients, clinicians and customers, as well as digital tools and processes for its workforce. Prat brings a wealth of experience leading this type of work across large scale, highly-matrixed organizations and will be instrumental in driving this shift across Kaiser Permanente.
Prior to Kaiser Permanente, Prat served as Chief Product and Experience Officer at The Home Depot where he was responsible for a consumer-centric product vision and strategy and driving user experience excellence across the company. He also served as vice president of Interconnected Experience at Home Depot, successfully launching a new digital online experience and cloud based-technology platform. Prat’s prior roles include vice president of Global Ecommerce, Product Management, and Analytics at Staples, Inc. and vice president of Product Development at Informed Clinical Sciences Corporation.
Prat holds a bachelor’s degree in computer science and engineering from the University of Madras and a master’s in business administration in global leadership and innovation from MIT’s Sloan School of Management.
Abhinav Shashank is the CEO and co-founder of Innovaccer, a leading San Francisco-based healthcare technology company. He built the foundation for Innovaccer’s success as a leader in population health management and machine learning-oriented healthcare solutions recognized by Gartner, KLAS, Forbes, and Black Book Market Research.
Abhinav’s continued efforts and ambition enabled the company to flourish in health information technology in the U.S. and acquire over 40 healthcare organizations as customers, with more than 37,000 providers using Innovaccer’s solutions daily. With his vision for seamless care delivery using unified patient records, Abhinav is now leading the team towards $1 billion in savings for U.S. healthcare. Additionally, Abhinav Shashank is an influential thought leader and a renowned author. Abhinav has published over 300 articles for various international media outlets, was bestowed a coveted spot in Forbes “30 Under 30 Asia 2017: Enterprise Tech” and was recognized by Becker's Hospital Review as one of the ‘Top 60 rising leaders in U.S. healthcare under 40’ in 2019.
Abhinav is a graduate of the Indian Institute of Technology at Kharagpur.
-
- 05/06/2022 | 10:05 am – 10:30 am PDT
- 25 mins Hall ASpeakers Zenia TataInnovation Strategist
Former Chief Impact Officer of Xprizehttps://www.linkedin.com/in/zenia-tata/ Dr. Billings has devoted his life to studying and teaching medicine and genetics, while accelerating the use of a broad range of novel genomic technologies in clinical settings. Over his decades in healthcare, he has established key business partnerships, driving adoption of innovative discoveries and commercial success. His leadership has been demonstrated by notable achievements - physician, researcher, founder, senior executive or director of multiple public and private companies, and scientific advisor for government entities.
Dr. Billings has held academic appointments at Harvard University, U.C. San Francisco, Stanford University, and U.C. Berkeley; and served as a board-certified internist and medical geneticist at leading medical centers. He has authored more than 225 scientific and medical publications. His published doctoral studies at Harvard were supervised by Dr. Baruj Benacerraf, who subsequently received the Nobel Prize in Medicine. In addition, he has served on the Scientific Advisory Board of the Food and Drug Administration (FDA), the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and as an appointee to the Secretary's Advisory Committee on Genetics, Health, and Society at the Department of Health and Human Services. His work on genetic discrimination was instrumental in the creation and passage of the federal Genetic Information Non-Discrimination Act of 2008. He holds an MD and a PhD in Immunology from Harvard, and an Artium Baccalaureus, summa cum laude from U.C. San Diego.
I serve as Head of R&D and Chief Medical Officer for Elicio Therapeutics, a Boston based biotechnology company advancing clinical development of a novel amphiphile vaccine for KRAS mutated solid tumors; KRAS mutations are found in 25% of all cancers. Our interdisciplinary project team is comprised of experts in preclinical development, translational immunology, clinical vaccine development and manufacturing. As the EVP of R&D and Chief Medical Officer of Elicio Therapeutics, I have extensive experience in translational biology and clinical development. I am also Associate Adjunct Professor of Urology at the University of California San Francisco. My primary research interest is development of novel immunoactivating therapeutics, such as the ELI-002 a novel first-in-class lymph node targeting vaccine targeting the seven most frequently mutated KRAS alleles that are observed in 25% of human tumors. I oversee a team of vaccine immunologists, clinical operations, research scientists, project management, regulatory and manufacturing technical operations staff and consultants who perform target validation, product development and translational research in a state of the art 10,000 square foot research facility at 451 D Street in the Seaport District of Boston, MA and a 250 square foot animal holding and procedure room suite at CRADL located in Cambridge, MA. I successfully administered projects supported by NIH grants, and projects in industry resulting from candidates originating with academic research that have resulted in FDA breakthrough designation and global marketing approvals for example, for Zytiga® (abiraterone acetate). Thus, I bring with me knowledge and leadership experience which will allow me to carry out my role successfully. Dr. Mahul Amin is an internationally recognized researcher, leading urologic pathologist and highly effective operations executive, with consistent success heading up clinical practice and research transformations in translational pathology, leading growth, and increasing industry recognition for large academic laboratories. He is an international consultant in tumors of the genitourinary tract and a world-renowned expert and educator in genitourinary pathology playing an active role in developing the 2002 and 2016 WHO classification systems for urologic cancers. Dr. Amin is also a thought leader in AI Diagnostics having developed several research papers on the topic. His scientific interests are in the discovery and validation of biomarkers in urologic malignancies for clinical personalized medicine. He has co-authored 13 books and published over 372 papers and 73 book chapters. Dr. Amin’s H Index is 112 and his i10 index is 383; his work has a total of 72,834 citations (as of July. 2020). Dr. Amin is a sought out speaker and has given over 400 pathology grand rounds, lectures and workshops. He has extensively spoken around the world and lectured in 31 countries and 75 cities outside of the US. He has made pioneering contributions including the first major descriptions of entities in genitourinary pathology including lymphoepithelioma-like carcinoma of the bladder, micropapillary carcinoma of the bladder, acquired cystic disease associated renal cell carcinoma, clear cell-papillary renal cell carcinoma, thyroid-like carcinoma of the kidney, tubulocystic carcinoma of the kidney, intratubular large cell hyalinizing sertoli cell neoplasia of the testis, and low-grade glandular tumors of the urachus. He has authored some of the first major series and descriptions on Succinate dehydrogenase - deficient renal cell carcinoma and Fumarate hydratase- deficient renal cell carcinoma and the classification of neuroendocrine tumors of the prostate. He hold/s leadership positions for the AJCC, CAP, WHO and several international organizations. Dr. Payel Das received her Ph.D. degree from Rice University in 2007. Currently, she is a principal research staff member and a manager at IBM Research AI, IBM Thomas J. Watson. Research Center, Yorktown Heights, New York, USA, 10597. She is an IBM Master Inventor, as well as an AI Horizons Network IBM-MILA principal investigator. Her research interests include statistical physics, trustworthy machine learning, neuro- and physics-inspired machine learning, and machine creativity. Das has co-authored over 50 peer-reviewed publications and over 30 filed patent disclosures, given dozens of invited talks at several university colloquiums, department seminars, top rated conferences, and workshops. She has served as an adjunct associate professor in the Applied Physics Applied Mathematics department at Columbia University, NY, and as an editorial advisory board member for the ACS Central Science journal. Das is the recipient of IBM Outstanding Technical Achievement Award (the highest technical award at IBM), as well as several IBM Research Accomplishment Awards and IBM Invention Plateaus. Her work has been recognized by the Harvard Belfer Center Technology and Public Purpose program and she was a member of the IBM team that received the National Medal on Innovation and Technology in 2009.
-
- 05/06/2022 | 10:35 am – 11:05 am PDT
- 30 mins Hall ASpeakers Lisa Davis is Senior Vice President and CIO at Blue Shield of California, a $21 billion nonprofit health plan serving 4.6 million members in California. She’s driving Blue Shield toward a future state of health care, transforming the IT business model and leveraging digital technology, data, and analytics to accelerate the delivery of capabilities to improve the member and provider experience. An innovative business executive, Davis’ future-forward vision has improved business outcomes and customer experiences for organizations in high-tech, academia, and the federal government. She led a global P&L at Intel prior to being the CIO at Georgetown University. She was also CIO of both the U.S. Marshals Service and Counterintelligence Field Activity. Lisa holds a Master of Science in Human Resources Management from Golden Gate University and a Bachelor of Science in Computer Engineering from Syracuse University. She serves on the board of Blue Shield of California Foundation. Diane BradyAsst Managing Editor
ForbesDiane Brady has interviewed many of the world's leading business and political figures throughout her career, along with managing far-flung teams and building groundbreaking editorial franchises. She is currently an assistant managing editor at Forbes, overseeing the editorial teams that run C-suite coverage, ForbesWomen, For(bes) the Culture, the 30 Under 30 franchise, and coverage of creators and startups. Prior to joining Forbes, she worked at McKinsey, Bloomberg Businessweek, The Wall Street Journal and Maclean’s, along with running her own company. Her book, Fraternity, was named one of Amazon’s best books of the year. Dwight French is a proven executive with over 20 years of successful business leadership and experience in the health insurance, provider, and life science sectors. His work serving healthcare includes executive positions at BearingPoint (formerly KPMG Consulting), SVP of Enterprise Product Management at HMS Holdings Corp (HMSY-US), Chief Business Development Officer at Santa Clara County IPA (SCCIPA), and co-founder of a population health management software company that a Fortune 20 strategic invested in and was successfully exited. Dwight has been working at the leading edge of healthcare reform since its inception. Described as an insightful leader, his innovative strategies exploit business opportunities that arise from this evolving reform. Dwight possesses the rare ability to craft policies and shape vision into actionable results. He accomplishes this unique skill through developing leaders, solid operational execution, effective communication and intentional relationship development.
-
- 05/06/2022 | 11:05 am – 11:35 am PDT
- 30 mins Hall ASpeakers Jonathan Norris is a managing director for business development in SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations.
In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than nineteen years of banking experience working with healthcare companies and venture capital firms.
Norris earned a bachelor's degree in business administration from the University of California, Riverside and a Juris Doctorate from Santa Clara University. Shahram is the Founder and General Partner of Civilization Ventures, a venture capital firm focused on supporting cutting edge innovations in health tech and biology. Prior to founding Civilization Ventures, Shahram was a life sciences entrepreneur and angel investor for more than a decade. Shahram was the founding CEO and later Executive Chairman of Rgenix, a biotech company with multiple first-in-class therapeutics for cancer now in Phase 2 clinical trials. Prior to Rgenix, he was founding CFO and VP of Corporate Development at NextBio, a genomics pioneer acquired by Illumina. Shahram sits on the boards of Rewrite and Foresight and has been one of the first checks into frontier tech companies such as Omada Health, CatalogDNA, Evonetix, BilliontoOne, Lemonaid Health, Outpace Bio, Ample, Avantome (acquired by Illumina), Bina (acquired by Roche), Rocket Pharma (IPO), and Counsyl (acquired by Myriad). Shahram began his career in Silicon Valley over twenty years ago at Wilson Sonsini and went on to advise some of the world's preeminent technology leaders while at Goldman Sachs. He earned his JD from Harvard Law School and obtained a BA in Economics from Pomona College. Shahram founded CV in 2017 to support innovations that could - with some luck and perseverance - improve human health, preserve the world's natural resources, and further our shared civilization. Mr. Dayton Misfeldt is a Partner at Decheng Capital and has been with the firm since January 2021.
Prior to joining Decheng Capital, Mr. Misfeldt was a Managing Director of Bay City Capital. At Bay City Capital, Mr. Misfeldt invested in biopharmaceutical companies and worked closely with management teams on strategic decision making, business development and positioning companies for exit opportunities through accessing the public markets or acquisition. Past investments include Cadence Pharmaceuticals (acquired by Mallinckrodt), Civitas Therapeutics (acquired by Acorda Therapeutics), Dermira (acquired by Eli Lilly), MAP Pharmaceuticals (acquired by Allergan), Nextwave Pharmaceuticals (acquired by Pfizer), Oculex Pharmaceuticals (acquired by Allergan), and Pharmion (acquired by Celgene), among others.
Prior to joining Bay City Capital, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. He began his career in consulting at LifeScience Economics.
Mr. Misfeldt received a BA in Economics from the University of California, San Diego.
Chirag ShahPrincipal
Define Ventureshttps://www.linkedin.com/in/chiragshah1016/
-
Track Chairs
Sutter Health
As Sutter Health's first Chief Innovation Officer, Chris Waugh applies his extensive experience in human-centered design to guide the integrated network's innovation strategy. Human-centered design is a creative approach that seeks personalized solutions to meet individual needs — understanding people and their behaviors, identifying trends and exploring solutions that improve a person's healthcare experience — in order to make healthcare more usable and accessible for patients, doctors and nurses. At Sutter, Waugh has spearheaded the digital transformation of healthcare and the implementation of Tera — a virtual-first medical practice which aims to best resolve issues before patients have to schedule an in-person appointment. This work is driven by the idea that healthcare should fit into the patient's life, and not the other way around. He is also passionate about taking on mental health issues and driving simpler, easier to navigate and more resonate healthcare for all patients. Before joining Sutter Health, Waugh held entrepreneurial leadership roles at IDEO, a globally regarded Bay Area design and innovation firm, and was vice president of design at One Medical Group in San Francisco where he helped create a culture of innovation. He is an affiliated member of both Rock Health and Innovation 50. He is an affiliated member of both Rock Health and Innovation 50. Waugh graduated from Fort Lewis College in Colorado, with bachelor's degrees in international business and French.
Mohan is the cofounder and CEO of iNDX.AI, a silicon valley based Healthcare Informatics Company focusing on Deep Data Analytics for Translation Research in Immuno Cancer Therapy and Covid-19 using AI/ML/NLP technologies. He is a serial entrepreneur with over 30 years of experience in successfully founding, establishing and exiting high-tech and Biotech start-ups in Silicon Valley, raising over $50M in funding and generating over $500M in shareholder value. He is an Angel Investor & serves on the BOD of Hemex Health, a very innovative point of care Malaria & Sickle cell Diagnostics Company. Mohan has joined Stanford University Medical School as a Research Scholar to work on developing new Socio-Economic business models that leverage innovation in affordable medical technology and transform the Health Care at the bottom of the pyramid in developing world, touching Billion Lives and creating Millions of jobs at the Micro & Macro levels. Mohan was the cofounder and CEO of iNDx LifeCare, a Point of Care Diagnostics Company, Oncomdx, an innovative Cancer Diagnostics company, which specialized, in integrated diagnostics (acquired by Core Diagnostics 2013). Mohan was the cofounder and CEO of BioImagene, a pioneer in Digital Pathology that was acquired by Roche in 2010 for $100M. He was the co-founder and CEO of Roamware Inc., a leading wireless roaming software company (acquired by Audax for $135M). He was also the cofounder and CEO of SoftPlus, an early provider of eCRM software for telecom carriers around the world. In March 2000, SoftPlus was sold to US Interactive for $360M. Before starting SoftPlus, Mohan co-founded and served as the CEO of Digital Tools Inc., a leader in enterprise project and resource management software (Acquired by Toofan, Inc.). He previously held various software development and management positions with Hewlett Packard and Intel Corporation.
Mohan holds a master's degree in computer science from the Florida Institute of Technology, a master's degree in electrical engineering from Bombay University and attended an Advanced Management Certificate Program at Stanford University. He is a founding charter member of TiE (The Indus Entrepreneurs), a Silicon Valley-based forum for entrepreneurs. He is on the board of several non-profit organizations such as EPPIC: Association of Biotech and Pharma Executives; ICC (CWC) - Health and Wellness Community Organization, IDE - a leading nonprofit devoted to the eradication of rural poverty worldwide; Drev - design revolution for the other 90% and DPA - Digital Pathology Association.
He lives in Cupertino California with his wife and 2 children, has run a marathon and Triathlon, is an avid trekker (trekked in all 7 continents, including Mt Kailash, Everest Base Camp (Himalayas), Kilimanjaro, Machu Picchu, Mont Blanc) and biked around Lake Tahoe (Tahoe Century) to help fund raising for cancer research.
TiEcon 2022 Tracks
- AI & Machine Learning
Artificial Intelligence & Machine Learning
All eyes on the business and human impact of AI
- Capital Markets
Capital Markets
Conversations from IPO to Exits, a 360 degree view on investments
- Cloud & SaaS
Cloud & SaaS
Exciting new paradigms in cloud and security with a zero-trust position
- Entrepreneurship
Entrepreneurship
Exploring the revolutionary future of entrepreneurship
- Global Connect
Global Connect
Scaling global connectivity post digital transformation
- Healthcare
Healthcare
Reinventing healthcare in the age of the global pandemic
- Media & Entertainment
Media & Entertainment
Convergence of Art and Technology
- Security & Fraud
Security & Fraud
Responding to Identity Theft, Fraud and Cybercrime
- Social Impact
- Supply Chain
Supply Chain
Recent Supply Chain Challenges - is there a Way Out?
- Sustainability
- TiE Youth
- Web3, Crypto & NFTs
Web 3, Crypto & NFTs
Bringing together the trends and the practical applications of Web3
-
Artificial Intelligence & Machine Learning
All eyes on the business and human impact of AI
-
Capital Markets
Conversations from IPO to Exits, a 360 degree view on investments
-
Cloud & SaaS
Exciting new paradigms in cloud and security with a zero-trust position
-
Entrepreneurship
Exploring the revolutionary future of entrepreneurship
-
Global Connect
Scaling global connectivity post digital transformation
-
Healthcare
Reinventing healthcare in the age of the global pandemic
-
Media & Entertainment
Convergence of Art and Technology
-
Security & Fraud
Responding to Identity Theft, Fraud and Cybercrime
-
Social Impact
Dare to Change the World for Good
-
Supply Chain
Recent Supply Chain Challenges - is there a Way Out?
-
Sustainability
Sustainability
-
TiE Youth
Fostering youth entrepreneurs
-
Web 3, Crypto & NFTs
Bringing together the trends and the practical applications of Web3